NAPLEX Quiz: Pharmaceutics
20 questions · exam conditions
0:00
PharmaceuticsQuestion 1 of 20

A 60-year-old male (weight 82 kg) with GERD reports persistent symptoms despite taking omeprazole delayed-release capsules 20 mg by mouth daily; he also takes calcium carbonate chewable tablets as needed and metformin immediate-release tablets 500 mg twice daily. He recently started taking omeprazole by opening the capsule and sprinkling contents into hot coffee to "help it dissolve." Labs: SCr 1.0 mg/dL (0.6–1.3), AST 26 U/L (10–40), ALT 24 U/L (7–56), Na 138 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). The pharmacist suspects reduced exposure due to improper dosage-form handling. Which factor most affects this drug's bioavailability?

Destruction of enteric coating leading to acid degradation of the drug before absorption
Increased solubility in hot liquids leading to excessive first-pass metabolism and reduced effect
Chelation with metformin in the stomach reducing absorption of omeprazole
Enhanced gastric acid secretion from calcium carbonate causing dose dumping of delayed-release pellets
← Back to quizzes

NAPLEX Quiz

NAPLEX Quiz: Pharmaceutics

Practice Pharmaceutics in NAPLEX with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Pharmaceutics, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 60-year-old male (weight 82 kg) with GERD reports persistent symptoms despite taking omeprazole delayed-release capsules 20 mg by mouth daily; he also takes calcium carbonate chewable tablets as needed and metformin immediate-release tablets 500 mg twice daily. He recently started taking omeprazole by opening the capsule and sprinkling contents into hot coffee to "help it dissolve." Labs: SCr 1.0 mg/dL (0.6–1.3), AST 26 U/L (10–40), ALT 24 U/L (7–56), Na 138 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). The pharmacist suspects reduced exposure due to improper dosage-form handling. Which factor most affects this drug's bioavailability?

  1. Destruction of enteric coating leading to acid degradation of the drug before absorption (correct answer)
  2. Increased solubility in hot liquids leading to excessive first-pass metabolism and reduced effect
  3. Chelation with metformin in the stomach reducing absorption of omeprazole
  4. Enhanced gastric acid secretion from calcium carbonate causing dose dumping of delayed-release pellets

Explanation: This question evaluates understanding of modified-release formulation integrity. The key patient-specific factor is the improper handling of omeprazole delayed-release capsules by sprinkling contents into hot coffee. The primary issue is destruction of the enteric coating on the pellets, which protects omeprazole from acid degradation in the stomach - exposure to hot liquids damages this coating, leading to drug degradation before it reaches its absorption site in the small intestine. Increased solubility affecting first-pass metabolism is not the mechanism of failure. Chelation with metformin is not a significant interaction for omeprazole. Calcium carbonate can reduce stomach acid but doesn't cause dose dumping of properly intact pellets. The pharmaceutical pearl is that enteric-coated and delayed-release formulations must maintain their coating integrity to ensure drug stability and proper site-specific delivery, and patients should be counseled to never expose these formulations to heat, crushing, or chewing.

Question 2

A 52-year-old woman (70 kg) with Roux-en-Y gastric bypass 2 years ago presents for uncontrolled hypothyroid symptoms. Current medications: levothyroxine 100 mcg tablet daily, calcium citrate 600 mg PO BID, omeprazole 20 mg delayed-release capsule daily. Labs: TSH 9.8 mIU/L (0.4–4.5), SCr 0.9 mg/dL (0.6–1.3), AST 20 U/L (10–40), ALT 19 U/L (7–56), Na 139 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The pharmacist suspects reduced absorption related to formulation and GI anatomy. Which factor most affects this drug's bioavailability in this patient?

  1. Increased first-pass hepatic metabolism due to weight loss after surgery
  2. Reduced gastric acidity and altered dissolution of the solid oral dosage form (correct answer)
  3. Increased renal clearance due to improved kidney function after surgery
  4. Enhanced absorption from increased intestinal surface area after bypass

Explanation: This question examines factors influencing bioavailability of thyroid hormone replacements in patients with altered GI anatomy. The key patient-specific factor is the history of Roux-en-Y gastric bypass, which reduces stomach size and alters pH, impacting drug dissolution. Reduced gastric acidity and altered dissolution of the solid oral dosage form is the primary factor as levothyroxine requires acidic conditions for optimal absorption, which are diminished post-bypass. Increased first-pass metabolism (choice A) is unlikely without hepatic changes, and enhanced absorption or renal clearance (choices C and D) do not align with bypass physiology that typically decreases absorptive surface. Increased intestinal surface area (choice D) is incorrect as bypass reduces effective absorptive area. A generalizable pearl is to monitor thyroid function closely in bariatric patients and consider dose adjustments or liquid formulations for better absorption. To ensure safety and efficacy, educate patients on separating levothyroxine from interfering substances like calcium or PPIs.

Question 3

A 52-year-old female (weight 70 kg) with severe xerostomia after radiation therapy cannot tolerate alcohol-containing mouthwashes and reports burning with commercial products. Current medications: pilocarpine 5 mg tablets by mouth three times daily, levothyroxine 100 mcg tablets daily, and fluoride toothpaste. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 19 U/L (10–40), ALT 17 U/L (7–56), Na 141 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The dentist requests a compounded alcohol-free mouth rinse containing lidocaine 2% for symptomatic relief; the pharmacy will prepare 200 mL and label for swish-and-spit use. What is the best compounding method for this preparation?

  1. Prepare a 2% lidocaine solution by dissolving lidocaine base directly in purified water without pH adjustment
  2. Compound using lidocaine HCl and an alcohol-free aqueous vehicle, ensuring complete dissolution and appropriate beyond-use dating for a water-containing oral rinse (correct answer)
  3. Use an ethanol-containing elixir as the vehicle to improve solubility and patient tolerability
  4. Incorporate lidocaine into an oleaginous base (e.g., mineral oil) to improve mucosal contact time for a mouth rinse

Explanation: This question addresses compounding considerations for patients with specific sensitivities. The key patient-specific factor is severe xerostomia with intolerance to alcohol-containing products, requiring an alcohol-free formulation. Using lidocaine HCl with an alcohol-free aqueous vehicle ensures complete dissolution while avoiding irritation, with appropriate beyond-use dating for water-containing preparations (typically 14 days refrigerated). Lidocaine base has poor water solubility without pH adjustment, making direct dissolution impractical. Ethanol-containing vehicles would cause burning and worsen xerostomia symptoms. Oleaginous bases like mineral oil are inappropriate for mouth rinses as they would be unpleasant and ineffective for swish-and-spit use. The pharmaceutical principle is that compounding for patients with xerostomia requires careful vehicle selection to avoid further irritation while ensuring drug solubility and stability, with water-based preparations requiring shorter beyond-use dates due to microbial growth risk.

Question 4

A 62-year-old man (78 kg) with dysphagia after head and neck cancer radiation is prescribed potassium chloride for hypokalemia. Current medications: potassium chloride 20 mEq extended-release tablets daily, hydrochlorothiazide 25 mg tablet daily. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 25 U/L (10–40), ALT 23 U/L (7–56), Na 134 mEq/L (135–145), K 3.1 mEq/L (3.5–5.0). He asks for a formulation that is easier to take and safer given his swallowing difficulty. Which formulation is most appropriate for this patient?

  1. Crush potassium chloride extended-release tablets and mix with applesauce
  2. Switch to potassium chloride oral liquid or powder packets for solution, administered with adequate dilution (correct answer)
  3. Continue extended-release tablets and advise taking without water to reduce choking risk
  4. Switch to enteric-coated potassium chloride tablets and split them in half for easier swallowing

Explanation: This question tests safe formulation options for electrolytes in patients with swallowing impairments. The key patient-specific factor is dysphagia increasing aspiration risk with solids. Switching to oral liquid or powder packets is most appropriate as it allows dilution and safe administration without choking hazards. Crushing extended-release or splitting enteric-coated (choices A and D) risks mucosal irritation or erratic release, and whole tablets without water (choice C) exacerbates risks. Continuation (choice C) ignores dysphagia. A pearl is to avoid modified-release potassium forms in dysphagia to prevent esophageal injury. For safety and efficacy, dilute liquids adequately and monitor potassium levels to correct hypokalemia without GI harm.

Question 5

A 34-year-old woman (65 kg) needs compounded progesterone vaginal suppositories due to an allergy to polyethylene glycol (PEG). Current medications: prenatal vitamin daily. Labs: SCr 0.7 mg/dL (0.6–1.3), AST 17 U/L (10–40), ALT 15 U/L (7–56), Na 140 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). The prescription is for progesterone 200 mg vaginal suppositories, dispense #30, PEG-free. What is the best compounding method for this preparation?

  1. Use a PEG suppository base to ensure rapid dissolution and uniform drug distribution
  2. Use a fatty suppository base (e.g., cocoa butter or a suitable hard fat) and incorporate progesterone via geometric dilution before molding (correct answer)
  3. Dissolve progesterone in water and pour into molds without a suppository base
  4. Crush oral progesterone capsules containing PEG excipients and mold into suppositories

Explanation: This question tests compounding methods for vaginal suppositories avoiding allergenic excipients. The key patient-specific factor is the PEG allergy, necessitating alternative bases. Using a fatty base like cocoa butter with geometric dilution is optimal for uniform progesterone distribution and mucosal release without allergen risk. PEG or water-based without base (choices A and C) may cause reactions or poor formation, and crushing capsules with PEG (choice D) introduces the allergen. Inadequate base (choice C) leads to instability. A pearl is to select lipophilic bases for hydrophobic drugs in suppositories to enhance bioavailability. For safety and efficacy, label for vaginal use and counsel on insertion to maximize therapeutic outcomes.

Question 6

A 27-year-old man (74 kg) is prescribed epinephrine auto-injectors for anaphylaxis and asks how to store them in his car year-round. Current medications: cetirizine 10 mg tablet daily PRN allergies. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 20 U/L (10–40), ALT 18 U/L (7–56), Na 139 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). He reports summer temperatures in his area often exceed 38°C (100°F). How should this medication be stored to maintain stability?

  1. Store the auto-injector in the car glovebox to keep it out of sight, regardless of temperature
  2. Store at controlled room temperature and protect from extreme heat/cold and light; avoid leaving it in a hot or freezing car (correct answer)
  3. Refrigerate the auto-injector daily and freeze it overnight to extend shelf-life
  4. Store in direct sunlight to prevent solution discoloration and crystallization

Explanation: This question evaluates storage practices for emergency injectables exposed to variable temperatures. The key patient-specific factor is year-round car storage in extreme temperatures, risking degradation. Storing at controlled room temperature protected from extremes is best as it preserves epinephrine stability and auto-injector functionality. Car glovebox or sunlight (choices A and D) exposes to heat/light, degrading the drug, while refrigeration/freezing (choice C) may impair mechanism or crystallize solution. Daily freezing (choice C) is impractical. A pearl is to avoid temperature excursions for catecholamines to prevent oxidation and loss of potency. For safety and efficacy, carry injectors on person and replace if exposed to extremes, ensuring readiness for anaphylaxis.

Question 7

A 58-year-old man (86 kg) with achlorhydria is started on ketoconazole for a fungal infection. Current medications: famotidine 20 mg tablet BID, calcium carbonate 1000 mg chewable PRN heartburn. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 29 U/L (10–40), ALT 31 U/L (7–56), Na 139 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). The pharmacist is asked why the patient may have reduced response to oral ketoconazole tablets. Which factor most affects this drug's bioavailability?

  1. Increased gastric pH reducing dissolution and absorption of a pH-dependent weak base (correct answer)
  2. Decreased hepatic blood flow increasing first-pass metabolism
  3. Increased renal clearance due to H2-blocker therapy
  4. Enhanced absorption due to concurrent calcium carbonate use

Explanation: This question investigates pH-dependent bioavailability of antifungal agents in gastric acid disorders. The key patient-specific factor is achlorhydria elevating gastric pH, impairing drug dissolution. Increased gastric pH reduces dissolution of ketoconazole, a weak base requiring acid for absorption, leading to poor bioavailability. Decreased hepatic flow or renal clearance (choices B and C) do not explain reduced response, and enhanced absorption from calcium (choice D) is incorrect as it may chelate. Increased metabolism (choice B) is unrelated. A pearl is to administer acid-requiring drugs with acidic beverages or switch formulations in hypochlorhydria. For safety and efficacy, monitor fungal response and consider alternatives like fluconazole if absorption is compromised.

Question 8

A 24-year-old woman (62 kg) picks up insulin glargine (U-100) prefilled pens for newly diagnosed type 1 diabetes. Current medications: insulin glargine pen 10 units SC nightly, insulin lispro pen per carb counting. Labs: SCr 0.7 mg/dL (0.6–1.3), AST 18 U/L (10–40), ALT 16 U/L (7–56), Na 137 mEq/L (135–145), K 4.3 mEq/L (3.5–5.0). She asks how to store her insulin pens to maintain stability, including the pen currently in use. How should this medication be stored to maintain stability?

  1. Store all pens in the freezer to prevent potency loss; thaw before use
  2. Refrigerate the in-use pen between doses and keep it in direct sunlight to warm before injection
  3. Store unopened pens refrigerated; keep the in-use pen at room temperature and discard after the labeled in-use period (correct answer)
  4. Store all pens at room temperature indefinitely as long as the solution remains clear

Explanation: This question tests proper storage conditions for biologic medications like insulin to maintain potency. The key patient-specific factor is the use of prefilled pens for a newly diagnosed type 1 diabetic, requiring education on handling to prevent degradation. Storing unopened pens refrigerated and keeping the in-use pen at room temperature with discard after the labeled period is optimal as it preserves insulin stability without freezing or heat exposure that could denature the protein. Freezing (choice A) or exposing to sunlight (choice B) risks potency loss through crystallization or degradation, while indefinite room temperature storage (choice D) ignores expiration guidelines. Refrigerating in-use pens (choice B) may cause discomfort upon injection. A pharmaceutical pearl is to always follow manufacturer storage guidelines for biologics to avoid temperature excursions that compromise efficacy. For patient safety, counsel on inspecting insulin for changes in appearance before use to ensure potency.

Question 9

A 67-year-old woman (58 kg) with Parkinson disease has worsening tremor and cannot swallow solid dosage forms reliably. Current medications: carbidopa/levodopa immediate-release 25/100 mg tablet TID, sertraline 50 mg tablet daily, docusate 100 mg capsule BID. Labs: SCr 1.1 mg/dL (0.6–1.3), AST 30 U/L (10–40), ALT 27 U/L (7–56), Na 136 mEq/L (135–145), K 3.9 mEq/L (3.5–5.0). Her caregiver asks for a formulation that can be administered without tablets while maintaining immediate-release dosing. Which formulation is most appropriate for this patient?

  1. Switch to carbidopa/levodopa extended-release tablets and crush them into applesauce
  2. Switch to an orally disintegrating carbidopa/levodopa formulation (if available) or an immediate-release-compatible liquid/dispersion per labeling (correct answer)
  3. Continue immediate-release tablets and advise chewing thoroughly to speed onset
  4. Switch to enteric-coated carbidopa/levodopa tablets for easier swallowing

Explanation: This question assesses formulation alternatives for Parkinson medications in patients with swallowing difficulties. The key patient-specific factor is unreliable swallowing of solid forms due to disease progression. Switching to an orally disintegrating or immediate-release liquid/dispersion formulation is most appropriate as it facilitates administration without altering pharmacokinetics, maintaining tremor control. Crushing extended-release or using enteric-coated forms (choices A and D) disrupts release profiles, potentially causing dose dumping or inefficacy, while chewing tablets (choice C) may not ensure complete absorption. Immediate-release tablets without modification (choice C) pose choking risks. A pharmaceutical pearl is to prioritize swallow-safe formulations in neurodegenerative diseases to prevent aspiration. For safety and efficacy, monitor for consistent symptom control and adjust doses based on clinical response.

Question 10

A 45-year-old man (80 kg) with epilepsy is stable on valproic acid delayed-release tablets but now has a jejunostomy (J-tube) and continuous feeds. Current medications: valproic acid delayed-release 500 mg tablet BID, pantoprazole 40 mg tablet daily. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 34 U/L (10–40), ALT 30 U/L (7–56), Na 138 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). The nurse asks what formulation change is most appropriate for J-tube administration. Which formulation is most appropriate for this patient?

  1. Crush the delayed-release valproic acid tablets and administer via J-tube to maintain the same release properties
  2. Switch to an immediate-release valproic acid liquid formulation suitable for enteral administration and adjust administration technique as needed (correct answer)
  3. Switch to an enteric-coated formulation and open the dosage form into the J-tube
  4. Continue delayed-release tablets and administer whole through the J-tube without flushing

Explanation: This question assesses formulation suitability for jejunal tube administration in epilepsy management. The key patient-specific factor is the J-tube with continuous feeds, bypassing stomach and potentially affecting delayed-release drugs. Switching to immediate-release valproic acid liquid is best as it allows direct jejunal absorption without release alteration, maintaining seizure control. Crushing delayed-release or using enteric-coated (choices A and C) disrupts pH-dependent release, risking toxicity or inefficacy, and whole administration (choice D) risks occlusion. Continuation without change (choice D) ignores tube compatibility. A pearl is to avoid extended-release forms in distal enteral tubes due to reduced transit time. Emphasizing safety, flush tubes adequately and monitor levels to ensure therapeutic efficacy without GI upset.

Question 11

A 78-year-old man (82 kg) is admitted for aspiration pneumonia and is now receiving continuous enteral nutrition via a nasogastric tube due to dysphagia after stroke. Current medications: phenytoin extended-release capsules 300 mg PO daily, amlodipine 5 mg tablet PO daily, atorvastatin 40 mg tablet PO nightly. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 28 U/L (10–40), ALT 25 U/L (7–56), Na 138 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). The team asks for a phenytoin option appropriate for administration through the feeding tube while minimizing formulation-related problems. Which formulation is most appropriate for this patient?

  1. Open the phenytoin extended-release capsules and mix the contents with water for tube administration
  2. Switch to phenytoin oral suspension and administer via tube with appropriate flushing and a feeding hold (correct answer)
  3. Crush phenytoin extended-release capsules into a fine powder and administer via tube
  4. Switch to phenytoin immediate-release tablets and administer whole through the tube without flushing

Explanation: This question tests the concept of appropriate formulation selection for enteral tube administration of antiepileptic medications. The key patient-specific factor is the use of a nasogastric tube with continuous enteral nutrition, which can interact with phenytoin and affect its absorption. Switching to phenytoin oral suspension is the best choice because it allows for proper administration via the tube while enabling feeding holds and flushing to minimize binding and precipitation issues, ensuring therapeutic levels. Opening or crushing extended-release capsules (choices A and C) is inappropriate as it destroys the controlled-release mechanism, potentially leading to erratic absorption or toxicity. Administering immediate-release tablets whole without flushing (choice D) risks tube occlusion and inadequate drug delivery due to lack of dissolution. A general pharmaceutical pearl is to always consider drug-formulation compatibility with enteral tubes and nutrition to prevent interactions that could compromise efficacy. Emphasizing patient safety, pharmacists should recommend holding feeds for phenytoin suspension to optimize absorption and prevent subtherapeutic levels.

Question 12

A 3-month-old infant (5.5 kg) needs omeprazole for suspected GERD, but the caregiver reports the infant develops hives with commercial flavored suspensions containing sodium benzoate. Current medications: vitamin D drops 400 IU daily. Labs: SCr 0.2 mg/dL (0.2–0.4), AST 30 U/L (10–40), ALT 22 U/L (7–56), Na 139 mEq/L (135–145), K 4.6 mEq/L (3.5–5.0). The prescriber requests a compounded omeprazole oral suspension without sodium benzoate, with instructions for a 14-day beyond-use date under refrigeration. What is the best compounding method for this preparation?

  1. Compound an omeprazole suspension using an alkaline vehicle (e.g., sodium bicarbonate-based) and avoid preservative-containing flavoring agents (correct answer)
  2. Compound an omeprazole suspension in an acidic vehicle to improve chemical stability
  3. Crush enteric-coated omeprazole tablets into water and store at room temperature for 60 days
  4. Dissolve omeprazole directly in purified water without pH adjustment to maximize stability

Explanation: This question assesses compounding stable oral suspensions for acid-labile drugs in infants with excipient sensitivities. The key patient-specific factor is hives from sodium benzoate, requiring preservative avoidance. Using an alkaline vehicle like sodium bicarbonate without preservative flavorings is best as it stabilizes omeprazole against acid degradation while ensuring safety and a short beyond-use date. Acidic vehicles or direct water dissolution (choices B and D) promote instability, and crushing enteric-coated tablets (choice C) destroys protection, reducing efficacy. Room temperature storage for 60 days (choice C) exceeds stability limits. A pearl is to adjust pH in compounding for drug-specific stability to optimize shelf-life. For pediatric safety and efficacy, refrigerate and shake well before use, monitoring for GERD symptom improvement.

Question 13

A 63-year-old man (84 kg) is prescribed alendronate 70 mg tablet weekly for osteoporosis but has severe esophageal stricture and cannot swallow tablets. Current medications: calcium carbonate 500 mg chewable BID, vitamin D3 1000 IU daily. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 26 U/L (10–40), ALT 24 U/L (7–56), Na 138 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). The prescriber asks for an alternative delivery approach that reduces swallowing risk while maintaining efficacy. What is the optimal drug delivery system for this patient?

  1. Continue oral alendronate and crush the tablet into yogurt to reduce esophageal irritation
  2. Switch to an intravenous bisphosphonate option administered at an appropriate interval (correct answer)
  3. Switch to enteric-coated alendronate tablets and instruct to take with food
  4. Switch to sublingual alendronate tablets dosed daily for improved absorption

Explanation: This question evaluates alternative delivery routes for bisphosphonates in patients with esophageal disorders. The key patient-specific factor is severe esophageal stricture preventing safe oral administration. Switching to intravenous bisphosphonates is optimal as it bypasses the GI tract, avoiding irritation while providing equivalent bone protection. Crushing or using enteric/sub-lingual forms (choices A, C, D) still risks esophageal exposure or altered absorption, and oral continuation (choice A) is hazardous. Sublingual (choice D) is not available for alendronate. A pearl is to reserve IV bisphosphonates for patients intolerant to oral forms to minimize infusion-related reactions. For efficacy and safety, ensure calcium/vitamin D co-administration and monitor bone density periodically.

Question 14

A 35-year-old man (90 kg) with asthma reports poor adherence to a twice-daily inhaled corticosteroid due to a busy schedule. Current medications: budesonide DPI 1 inhalation BID, albuterol HFA 2 puffs q4–6h PRN. Labs: SCr 0.8 mg/dL (0.6–1.3), AST 24 U/L (10–40), ALT 26 U/L (7–56), Na 140 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). He requests a delivery method that improves compliance while maintaining controller therapy. What is the optimal drug delivery system for this patient?

  1. Switch to nebulized budesonide administered four times daily for better lung deposition
  2. Switch to a once-daily inhaled corticosteroid option delivered via DPI or MDI as appropriate (correct answer)
  3. Switch to oral budesonide capsules to avoid inhaler technique issues
  4. Continue twice-daily DPI and advise doubling the dose once weekly to make up missed doses

Explanation: This question evaluates drug delivery systems for asthma controller therapy to enhance adherence. The key patient-specific factor is the busy schedule leading to poor compliance with twice-daily dosing. Switching to a once-daily inhaled corticosteroid via DPI or MDI is best as it simplifies the regimen, improving adherence while maintaining lung-targeted delivery and efficacy. Nebulized or oral options (choices A and C) may reduce convenience or increase systemic effects, and doubling doses (choice D) risks inconsistent control and side effects. Continuing the current DPI without regimen change (choice D) ignores adherence barriers. A key pearl is to match delivery systems to lifestyle factors for chronic conditions to optimize long-term control. Emphasizing safety, pharmacists should assess inhaler technique regularly to ensure effective drug deposition and asthma management.

Question 15

A 40-year-old man (75 kg) has severe contact dermatitis and needs a topical corticosteroid, but he has a confirmed allergy to propylene glycol and requests a compounded preparation. Current medications: none. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 21 U/L (10–40), ALT 20 U/L (7–56), Na 141 mEq/L (135–145), K 4.4 mEq/L (3.5–5.0). The prescription is for compounded hydrocortisone 2.5% topical preparation, 60 g, propylene glycol–free, for application BID. What is the best compounding method for this preparation?

  1. Levigation of hydrocortisone powder with a small amount of mineral oil, then geometric dilution into a propylene glycol–free ointment base (correct answer)
  2. Dissolve hydrocortisone powder directly in propylene glycol to enhance solubility, then incorporate into a cream base
  3. Triturate hydrocortisone powder with water to form a solution, then add to an anhydrous ointment base without mixing
  4. Crush hydrocortisone tablets containing propylene glycol excipients and incorporate into a gel base

Explanation: This question tests compounding techniques for topical preparations avoiding specific excipients. The key patient-specific factor is the confirmed allergy to propylene glycol, requiring an excipient-free base. Levigation with mineral oil followed by geometric dilution into a propylene glycol-free ointment base is optimal as it ensures uniform drug distribution and stability without allergen exposure. Using propylene glycol for dissolution or crushing tablets with it (choices B and D) risks allergic reactions, and trituration with water (choice C) may lead to instability in an anhydrous base. Inadequate mixing (choice C) could cause uneven potency. A general pearl is to use geometric dilution in compounding to achieve homogeneity and prevent clumping. To promote safety, always document allergen avoidance in compounded products and counsel on application techniques for efficacy.

Question 16

A 70-year-old woman (64 kg) with chronic pain is prescribed morphine but has difficulty swallowing and frequent nausea. Current medications: ondansetron ODT 4 mg q8h PRN, acetaminophen 500 mg tablet q6h PRN. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 28 U/L (10–40), ALT 25 U/L (7–56), Na 137 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The prescriber wants a non-oral delivery method to improve adherence and maintain steady analgesia. What is the optimal drug delivery system for this patient?

  1. Immediate-release oral morphine solution dosed every 2 hours around the clock
  2. Transdermal fentanyl patch (when clinically appropriate) for sustained delivery and reduced pill burden (correct answer)
  3. Crushed extended-release morphine tablets mixed in water and administered as a slurry
  4. Sublingual sustained-release morphine tablets taken once weekly

Explanation: This question examines non-oral delivery options for chronic pain management in patients with GI issues. The key patient-specific factor is difficulty swallowing and nausea, hindering oral adherence. Transdermal fentanyl is optimal for sustained analgesia with reduced pill burden, bypassing GI absorption for steady levels. Frequent oral dosing or crushing extended-release (choices A and C) increases nausea risk or alters release, while sublingual sustained-release (choice D) is unavailable. Immediate-release slurry (choice C) poses safety risks. A pearl is to use transdermal systems for opioid-naive patients cautiously, titrating slowly. For safety and efficacy, monitor for respiratory depression and rotate patch sites to prevent skin irritation.

Question 17

A 71-year-old man (76 kg) with atrial fibrillation has a PEG tube and cannot swallow tablets. Current medications: apixaban 5 mg tablet BID, metoprolol tartrate 25 mg tablet BID, furosemide 20 mg tablet daily. Labs: SCr 1.2 mg/dL (0.6–1.3), AST 27 U/L (10–40), ALT 24 U/L (7–56), Na 137 mEq/L (135–145), K 3.8 mEq/L (3.5–5.0). The nurse asks which oral anticoagulant formulation approach is most appropriate for tube administration based on pharmaceutic considerations. Which formulation is most appropriate for this patient?

  1. Crush apixaban tablets and administer via PEG with water flushes per institutional policy and available data (correct answer)
  2. Switch to an enteric-coated anticoagulant tablet and crush it to improve absorption
  3. Open a hypothetical apixaban extended-release capsule and administer the beads via PEG
  4. Administer apixaban tablets whole through the PEG without flushing to prevent drug loss

Explanation: This question tests formulation adaptations for oral anticoagulants in patients with feeding tubes. The key patient-specific factor is the inability to swallow tablets, requiring tube-compatible administration. Crushing apixaban tablets and administering via PEG with flushes is appropriate per data, as it maintains bioavailability without altering the immediate-release profile. Enteric-coated or extended-release options (choices B and C) are hypothetical or unsuitable for crushing, risking efficacy loss, and whole administration without flushing (choice D) may cause occlusion. Hypothetical capsules (choice C) do not exist for apixaban. A pearl is to consult compatibility resources for tube administration to avoid interactions or blockages. To ensure safety, confirm crushing does not affect stability and monitor coagulation parameters for efficacy.

Question 18

A 16-year-old boy (60 kg) with ADHD is having difficulty remembering a midday dose at school. Current medications: methylphenidate immediate-release 10 mg tablet at 7 AM and 12 PM. Labs: SCr 0.7 mg/dL (0.6–1.3), AST 23 U/L (10–40), ALT 21 U/L (7–56), Na 140 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). His parent requests a delivery option that improves adherence while maintaining therapeutic coverage during school hours. What is the optimal drug delivery system for this patient?

  1. Switch to a long-acting methylphenidate extended-release oral dosage form taken once daily in the morning (correct answer)
  2. Switch to methylphenidate immediate-release and instruct to take both doses together each morning
  3. Switch to sublingual methylphenidate tablets dosed every 2 hours for rapid onset
  4. Switch to crushed methylphenidate immediate-release tablets mixed into a sports drink and sipped all day

Explanation: This question evaluates delivery systems for ADHD medications to address adherence challenges in adolescents. The key patient-specific factor is forgetting midday doses at school, complicating symptom control. Switching to a long-acting extended-release oral form taken once daily is optimal as it provides sustained coverage without school dosing, enhancing compliance and efficacy. Combining doses or using sublingual/crushed forms (choices B, C, D) risks peaks/troughs or altered pharmacokinetics, potentially causing side effects or inefficacy. Immediate-release without extension (choice B) ignores adherence issues. A pharmaceutical pearl is to select extended-release formulations for school-aged patients to minimize disruptions and stigma. For safety and efficacy, titrate doses based on symptom response and monitor for growth or cardiovascular effects.

Question 19

A 45-year-old female (weight 64 kg) with Crohn disease status post ileal resection reports worsening neuropathic pain despite adherence. Current medications: gabapentin 600 mg immediate-release tablets by mouth three times daily, ferrous sulfate 325 mg by mouth daily, and pantoprazole delayed-release tablets 40 mg by mouth daily. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 20 U/L (10–40), ALT 19 U/L (7–56), Na 139 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The pharmacist is asked which pharmaceutical factor is most likely to affect oral drug bioavailability in a patient with significant small-bowel resection. Which factor most affects this drug's bioavailability?

  1. Increased gastric emptying time increases the extent of absorption for most immediate-release drugs
  2. Reduced intestinal surface area decreases the extent of absorption for drugs absorbed in the small intestine (correct answer)
  3. Higher bile salt concentrations after ileal resection increase dissolution of all drugs and improve absorption
  4. Increased hepatic first-pass metabolism is the primary determinant of reduced absorption after bowel resection

Explanation: This question addresses factors affecting oral drug bioavailability after bowel resection. The key patient-specific factor is the history of ileal resection for Crohn disease, which significantly reduces the intestinal surface area available for drug absorption. Reduced intestinal surface area is the primary factor decreasing the extent of absorption for drugs absorbed in the small intestine, particularly those with site-specific absorption like gabapentin. Increased gastric emptying time would actually increase, not decrease, absorption for most immediate-release drugs by prolonging contact time. Bile salt concentrations typically decrease (not increase) after ileal resection, and while this affects lipophilic drug absorption, it's not the primary factor. Hepatic first-pass metabolism is not directly affected by bowel resection. The pharmaceutical pearl is that patients with significant small bowel resection may require higher doses or more frequent administration of medications to achieve therapeutic effects, and monitoring for therapeutic response is essential.

Question 20

A 34-year-old female (weight 58 kg) with moderate persistent asthma reports poor adherence because she forgets multiple daily doses. Current medications: albuterol HFA 90 mcg/actuation, 2 puffs every 4–6 hours as needed; budesonide nebulizer suspension 0.5 mg/2 mL twice daily (often missed); and montelukast 10 mg tablet nightly. Labs: SCr 0.7 mg/dL (0.6–1.3), AST 18 U/L (10–40), ALT 16 U/L (7–56), Na 140 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). She prefers a device that is portable and reduces administration time while maintaining effective inhaled corticosteroid delivery. What is the optimal drug delivery system for this patient?

  1. Continue nebulized budesonide twice daily because nebulizers provide superior lung deposition for all adults
  2. Switch to an inhaled corticosteroid as a once-daily dry powder inhaler (DPI) if she can generate adequate inspiratory flow (correct answer)
  3. Switch to an oral corticosteroid solution daily to avoid inhalation technique issues
  4. Use intranasal corticosteroid spray daily as a substitute for inhaled corticosteroid therapy

Explanation: This question evaluates selection of appropriate inhalation devices based on patient-specific factors. The key patient factor is poor adherence due to forgetting multiple daily doses, combined with the desire for portability and reduced administration time. A once-daily dry powder inhaler (DPI) is optimal if the patient can generate adequate inspiratory flow (typically >30-60 L/min depending on device) because it offers convenient once-daily dosing, portability, and quick administration. Continuing nebulized therapy doesn't address the adherence issue and is time-consuming. Oral corticosteroids are inappropriate for routine asthma control due to systemic side effects. Intranasal corticosteroids don't provide adequate lung deposition for asthma control. The pharmaceutical pearl is that device selection should consider patient factors including adherence patterns, lifestyle, and ability to use the device correctly, with DPIs offering advantages for patients who can generate adequate inspiratory flow and prefer portable, quick-administration options.